0.3% hypromellose
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Corneal Epithelium Defect
Conditions
Corneal Epithelium Defect
Trial Timeline
Oct 1, 2007 → Oct 1, 2009
NCT ID
NCT00598689About 0.3% hypromellose
0.3% hypromellose is a approved stage product being developed by Novartis for Corneal Epithelium Defect. The current trial status is completed. This product is registered under clinical trial identifier NCT00598689. Target conditions include Corneal Epithelium Defect.
What happened to similar drugs?
2 of 3 similar drugs in Corneal Epithelium Defect were approved
Approved (2) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00598689 | Approved | Completed |
Competing Products
12 competing products in Corneal Epithelium Defect